The Dopamine Receptor D1(DRD1) as Target for Developinga Therapy for Cocaine Addiction |Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.16, No. 5)Publication Date: 2022-06-28
Authors : Jill Harp; Kiayia Propst;
Page : 542-545
Keywords : Connectivity Map; DRD1; Cocaine; Loxpine; Olanzapine;
Abstract
It takes approximately fifteen years and nearly one billion dollars to bring a drug to market. A computational approach shows promise in being used to find therapeutics in less time and cost-effectively [1]. The approach reported herein mines publicly available gene expression data to uncover a gene is up or down regulated from microarray experiments and may lead to the repurposing of a current Food and Drug Administration (FDA)-approved drug to help cure cocaine addiction. Publicly available data from National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/) was used. Data sets were downloaded to uncover the gene expression difference between saline and cocaine-treated rats and the top genes analyzed. The secondary analysis included the correlation with FDA-approved drug gene expression data found on the Broad Institute's Connectivity Map (CMap: https://clue.io/cmap) website. This resulted in the identification of compounds that antagonize the dopamine receptor D1(DRD1).
Other Latest Articles
- A Brief Survey on the Advances of COVID-19 Treatment: With a New Suggestion to Capture Coronavirus by Magnetic Nanoparticles |Biomedgrid
- Some Ethical Problems in Psychotherapy of Unhappiness |Biomedgrid
- Professional Readiness of a Teacher for Innovative Activities: a Qualitative Aspect
- Health-Promoting Models of Behavior of Foreign Children in Polish Schools: Research Study
- Digital Competence Among the Key Components of Future Masters of Primary Education Professional Training: Theoretical Interpretations
Last modified: 2024-04-17 21:56:44